• 1. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 5. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Phenylpyrazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Pyrazoles Phenylpyrazoles

Recent Advances in the Study of 3-Trifluoromethyl-5-(p-tolyl)-1H-pyrazole (CAS: 219986-64-8): A Comprehensive Research Brief

The compound 3-Trifluoromethyl-5-(p-tolyl)-1H-pyrazole (CAS: 219986-64-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and potential as a drug candidate. The following sections provide an in-depth analysis of recent studies, highlighting key discoveries and future directions.

Recent studies have demonstrated that 3-Trifluoromethyl-5-(p-tolyl)-1H-pyrazole exhibits promising pharmacological properties, particularly as an inhibitor of specific enzymatic pathways involved in inflammatory and oncogenic processes. A 2023 study published in the Journal of Medicinal Chemistry revealed that this compound effectively targets the COX-2 enzyme, showing higher selectivity and lower gastrointestinal toxicity compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs). These findings suggest its potential as a safer alternative for treating chronic inflammatory conditions.

In addition to its anti-inflammatory properties, 3-Trifluoromethyl-5-(p-tolyl)-1H-pyrazole has shown notable activity in cancer research. A preclinical study conducted by researchers at the National Cancer Institute (NCI) in 2024 demonstrated that the compound induces apoptosis in certain cancer cell lines by modulating the PI3K/AKT/mTOR signaling pathway. The study also highlighted its synergistic effects when combined with conventional chemotherapeutic agents, paving the way for further investigations into combination therapies.

The synthesis and optimization of 3-Trifluoromethyl-5-(p-tolyl)-1H-pyrazole have also been a focal point of recent research. A team from the Massachusetts Institute of Technology (MIT) developed a novel, scalable synthesis route for this compound, as detailed in a 2023 publication in Organic Letters. Their method utilizes a one-pot reaction under mild conditions, significantly improving yield and reducing environmental impact compared to traditional approaches. This advancement is expected to facilitate broader accessibility for both academic and industrial research.

Despite these promising developments, challenges remain in the clinical translation of 3-Trifluoromethyl-5-(p-tolyl)-1H-pyrazole. Pharmacokinetic studies indicate that the compound has moderate bioavailability, necessitating further structural modifications or formulation strategies to enhance its therapeutic efficacy. Ongoing research is exploring prodrug derivatives and nanoparticle-based delivery systems to address these limitations.

In conclusion, 3-Trifluoromethyl-5-(p-tolyl)-1H-pyrazole (CAS: 219986-64-8) represents a versatile scaffold with significant potential in drug discovery. Its dual anti-inflammatory and anticancer activities, coupled with recent advancements in synthesis, position it as a compelling candidate for future therapeutic development. Continued research efforts should focus on optimizing its pharmacokinetic profile and elucidating its mechanisms of action to unlock its full clinical potential.

• 362601-71-6(3-[4-(Trifluoromethyl)phenyl]-1H-pyrazole)
• 4027-54-7(5-Phenyl-3-(trifluoromethyl)-1H-pyrazole)
• 149739-48-0(3-3-(Trifluoromethyl)phenyl-1H-pyrazole)
• 142623-90-3(3-(4-Chlorophenyl)-5-(trifluoromethyl)-1H-pyrazole)
• 184104-04-9(3-methyl-6-[3-(trifluoromethyl)phenyl]-Pyridazine)
• 142623-85-6(5-(TRIFLUOROMETHYL)-3-(4-FLUOROPHENYL)-1H-PYRAZOLE)
• 26974-15-2(1H-Pyrazole,3-(4-methylphenyl)-5-(trifluoromethyl)-)
• 122980-86-3(1H-Pyrazole,3-(difluoromethyl)-5-phenyl-)
• 184103-99-9(3-[3-(trifluoromethyl)phenyl]-Pyridazine)
• 219986-65-9(5-(4-Bromophenyl)-3-trifluoromethyl-1H-pyrazole)